462 related articles for article (PubMed ID: 26349573)
21. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
23. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
24. Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.
Manenti G; Cicciò C; Squillaci E; Strigari L; Calabria F; Danieli R; Schillaci O; Simonetti G
Eur J Radiol; 2012 Aug; 81(8):1917-25. PubMed ID: 21908120
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.
De Paepe KN; Van Keerberghen CA; Agazzi GM; De Keyzer F; Gheysens O; Bechter O; Wolter P; Dierickx D; Janssens A; Verhoef G; Oyen R; Koole M; Vandecaveye V
Radiol Imaging Cancer; 2021 Mar; 3(2):e200061. PubMed ID: 33817648
[TBL] [Abstract][Full Text] [Related]
26. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).
Bernstine H; Domachevsky L; Nidam M; Goldberg N; Abadi-Korek I; Shpilberg O; Groshar D
Medicine (Baltimore); 2018 Apr; 97(16):e0490. PubMed ID: 29668631
[TBL] [Abstract][Full Text] [Related]
28. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
[TBL] [Abstract][Full Text] [Related]
29. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
[TBL] [Abstract][Full Text] [Related]
30. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
31. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis.
Li B; Li Q; Nie W; Liu S
Eur J Radiol; 2014 Feb; 83(2):338-44. PubMed ID: 24355655
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
34. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
35. Whole-Body Diffusion-Weighted MRI Compared to
Shapira-Zaltsberg G; Wilson N; Trejo Perez E; Abbott L; Dinning S; Kapoor C; Davila J; Smith B; Miller E
Can Assoc Radiol J; 2020 May; 71(2):217-225. PubMed ID: 32062992
[TBL] [Abstract][Full Text] [Related]
36. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
38. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
39. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
40. Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.
Afaq A; Fraioli F; Sidhu H; Wan S; Punwani S; Chen SH; Akin O; Linch D; Ardeshna K; Lambert J; Miles K; Groves A; Kayani I
Clin Nucl Med; 2017 Jan; 42(1):e1-e7. PubMed ID: 27607161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]